Extended Data Fig. 6: Characterization of FK506-treated C57Bl6N mice using pump following MI.
From: Targeting calcineurin induces cardiomyocyte proliferation in adult mice
(a-h) Delivery of FK506 treatment by osmotic pump from 1-7 weeks post MI was similar to DMSO vehicle control treatment for: (a) The heart weight/body weight; (b) Heart weight. (c) Body weight. (d-h) Serial echocardiography of injury DMSO Ctrl and FK506-treated mice for: (d) diastolic anterior wall thickness; (e) diastolic posterior wall thickness; (f) heart rate; (g) diastolic left ventricular internal dimension; (h) systolic left ventricular internal dimension. (i-p) Delivery of FK506 treatment by osmotic pump from 4-8 weeks post MI was similar to DMSO vehicle control treatment for: (i) The heart weight/body weight; (j) Heart weight. (k) Body weight. (l-p) Serial echocardiography of injury DMSO Ctrl and FK506-treated mice for: (l) diastolic anterior wall thickness; (m) diastolic posterior wall thickness; (n) heart rate; (o) diastolic left ventricular internal dimension; (p) systolic left ventricular internal dimension. Data are mean ± s.e.m.; unpaired two-sided t-test. Sample numbers, n = 4 for DMSO-treated and n = 5 for FK506-treated hearts (a-h), n = 3 for DMSO-treated and n = 4 for FK506-treated hearts (i-p).
